Arrowstreet Capital’s Blueprint Medicines BPMC Stock Holding History

Arrowstreet Capital’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-29,562	Closed	-$3.79M	–	1882
2025 Q2	$3.79M	Buy	+29,562	New	+$3.07M	﹤0.01%	1262
2020 Q1	–	Sell	-59,988	Closed	-$4.81M	–	1877
2019 Q4	$4.81M	Buy	+59,988	New	+$4.49M	0.01%	869
2018 Q3	–	Sell	-15,507	Closed	-$984K	–	1091
2018 Q2	$984K	Buy	+15,507	New	+$1.23M	﹤0.01%	811
2018 Q1	–	Sell	-3,100	Closed	-$234K	–	1131
2017 Q4	$234K	Buy	+3,100	New	+$218K	﹤0.01%	1160

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Arrowstreet Capital's BPMC Position: Q3 2025 in Review

Arrowstreet Capital sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 29,562 shares — an estimated $3.79M sold.

Arrowstreet Capital first reported a position in BPMC in Q4 2017 and held it in 4 quarters. The position peaked at $4.81M in Q4 2019. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Arrowstreet Capital reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Arrowstreet Capital sold 29,562 Blueprint Medicines shares in Q3 2025, an estimated $3.79M.
Arrowstreet Capital first reported a position in Blueprint Medicines in Q4 2017 and held it in 4 quarters.
Arrowstreet Capital's Blueprint Medicines position peaked at $4.81M in Q4 2019.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Arrowstreet Capital's 13F filing for Q3 2025, filed 13 Nov 2025.